US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.

Nathan D WongHridhay KarthikeyanWenjun Fan

Published in: Cardiovascular drugs and therapy (2023)

Semaglutide treatment in eligible US adults may substantially reduce obesity prevalence and CVD events, which may dramatically impact associated healthcare costs.

Keyphrases

cardiovascular disease
healthcare
type diabetes
metabolic syndrome
insulin resistance
risk factors
weight loss
adipose tissue
body mass index
coronary artery disease
replacement therapy